Psychopharmacology
May 16, 2008
Karsten Heekeren, Jörg Daumann, Anna Neukirch et al.
158 citations
Both S-ketamine (an NMDA antagonist) and DMT (a 5HT2A agonist) reduced mismatch negativity (MMN) and impaired performance on a continuous performance test in healthy volunteers, but the effects differed. S-ketamine produced a more pronounced overall reduction in MMN and specifically affected the frontal source of MMN, while DMT did not. These distinct neurocognitive profiles suggest that the two classes of hallucinogens model different aspects of psychosis.
The World Journal of Biological Psychiatry
March 1, 2010
Patrik Roser, Franz X. Vollenweider, Wolfram Kawohl
63 citations
Delta(9)-Tetrahydrocannabinol (THC), the main psychoactive component of cannabis, can cause psychomotor effects, psychotic reactions, and cognitive impairment similar to schizophrenia. These effects can be reduced by two other cannabinoids: cannabidiol (CBD) and SR141716. CBD, the second most abundant cannabis constituent, weakly antagonizes the CB(1) receptor, inhibits anandamide reuptake and hydrolysis, and has neuroprotective antioxidant activity. SR141716 is a potent and selective CB(1) receptor antagonist. Both can reverse many effects of CB(1) receptor agonists, suggesting antipsychotic properties. Experimental studies in animals, healthy volunteers, and schizophrenic patients support this, with a pharmacological profile similar to atypical antipsychotic drugs. This review presents preclinical and clinical studies on the potential antipsychotic effects of CBD and SR141716.